RVU120

TERMINATED · PHASE2 · Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome

Sponsor decision

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.